Group 1 - The Shanghai Composite Index rose by 0.5% to close at 3665.92 points, while the Hang Seng Index increased by 0.25% to 24969.68 points [1] - CanSino Biologics has an AH premium of 91.3%, ranking 35th among AH shares. The A-shares closed at 82.5 yuan, down 3.06%, and the H-shares closed at 47.08 HKD, down 6.96% [1] - CanSino Biologics, founded in 2009 in China, focuses on providing innovative, high-quality, and accessible vaccines for the prevention and treatment of infectious diseases, positioning itself as a leading high-tech biopharmaceutical company [1] Group 2 - The company's mission is to provide innovative, high-quality, and accessible vaccines globally, aiming for the vision of "Innovation without end, a world without epidemics" [1] - CanSino Biologics is listed on both the Hong Kong Stock Exchange (H shares, stock code 6185.HK) and the Shanghai Stock Exchange's STAR Market (A shares, stock code 688185), being the first "A+H" vaccine stock since the launch of the STAR Market [1]

Core Viewpoint - The Chinese innovative pharmaceutical industry is transitioning from imitation-based innovation to original innovation, and there is a strong emphasis on expanding into emerging overseas markets to achieve high-quality development [1][2]. Group 1: Industry Insights - Since the reform of the drug review and approval system in 2015, China's innovative drugs have entered a rapid development phase [1]. - Experts at the "Future Path of Chinese New Drugs (T20+)" conference suggested that collaboration among various stakeholders is essential to accelerate the internationalization of innovative drugs [1]. - The potential market in developing countries is significant due to their large populations, and China's innovative drugs are seen as high-quality and affordable alternatives [1]. Group 2: Company Initiatives - Companies like BeiGene, China Biologic Products, and CanSino Biologics are taking proactive steps to promote their innovative drugs in developing countries, contributing to global health challenges such as infectious diseases and chronic illnesses [1]. - A new alliance called the "Emerging Market New Drug Product Export Alliance" was established to facilitate experience sharing and collaborative efforts in promoting products to more countries [2].

Investment Rating - The industry investment rating is maintained at "Overweight" [3][10][29] Core Viewpoints - The vaccine industry is experiencing significant innovation breakthroughs both domestically and internationally, with multiple companies achieving clinical trial approvals for new vaccines [2][6][10] - The industry is currently facing performance pressure due to supply-demand imbalances, with high competition leading to price declines for some products [10][29] - Long-term prospects remain positive, driven by policy support, increasing demand due to aging populations, and ongoing technological advancements in vaccine development [11][31] Summary by Sections Recent Developments - Watson Bio's mRNA vaccine for respiratory syncytial virus (RSV) has received clinical trial approval, marking a significant step in domestic vaccine innovation [5][6] - The first phase trial of China's Tian Tan strain HIV vaccine has been successfully completed, indicating progress in HIV vaccine research [5][6] - Pfizer reported a 10% revenue growth in Q2 2025, exceeding market expectations, with significant contributions from its anticoagulant and COVID-19 products [5][6] Market Performance - The vaccine sector saw a slight decline of 0.44% last week, while the overall pharmaceutical sector dropped by 0.84% [7][8] - The vaccine industry has shown a cumulative increase of 0.96% since the beginning of 2025, indicating a recovery trend [7][8] Valuation Metrics - The vaccine sector's price-to-earnings (PE) ratio is 80.76X, with a recent decrease of 0.33X, while the price-to-book (PB) ratio stands at 1.96X [9][10] - The PE ratio is within the 48.20% percentile since 2013, indicating a relatively high valuation compared to historical data [9][10] Investment Recommendations - The report suggests focusing on companies with strong innovation capabilities and differentiated products, recommending companies like CanSino and Kanghua Bio [10][31] - The long-term outlook emphasizes the importance of innovation and international expansion as key drivers for growth in the vaccine industry [10][31]

Market Overview - The A-share market showed strong performance with the Shanghai Composite Index steadily rising, while the Hong Kong stock market experienced a narrow fluctuation, closing up by 0.03% [1] - Concerns in the market are heightened due to the U.S. President Trump's shortened ultimatum for sanctions against Russia, now set at 10 days, with potential impacts on India and other countries [1] - The U.S. is also set to impose significant tariffs on semiconductor chips and pharmaceuticals, with drug tariffs reaching as high as 250% [1] Company Developments - Jingtai Technology announced a pipeline cooperation agreement with DoveTree worth approximately HKD 470 billion (USD 59.9 billion), leading to a stock surge of over 12% [2] - A-share company Weixin New Materials faced regulatory scrutiny after a stock price surge related to the "embodied intelligent robot" concept and control change expectations [2] - The Shanghai government released a plan for the development of the embodied intelligence industry, aiming for breakthroughs in core algorithms and technologies by 2027 [2] Industry Trends - The 2025 World Robot Conference is set to showcase over 100 new products, nearly double from last year, indicating a growing interest in robotics [3] - The U.S. student loan delinquency rate has reached 12.9%, the highest in 21 years, which may influence Federal Reserve decisions on interest rates [3] - The steel and paper industries are experiencing positive momentum, with companies like Maanshan Steel and Nine Dragons Paper seeing significant stock price increases [3] Defense Sector Insights - The military industry is gaining traction with significant contracts, such as the sale of the Hongqi-9 air defense system and the export of submarines to Pakistan [4] - China Shipbuilding Defense announced a profit increase of 213.25% to 267.73% for the first half of the year, leading to a stock rise of nearly 8% [4] Consumer Market Activity - The new consumption sector is becoming active, with companies like Pop Mart seeing increased attention at recent toy exhibitions [5] - The liquor industry is also responding to market trends, with new product launches and stock price increases [5] Aviation Sector Developments - Cathay Pacific announced an $8.1 billion order for 14 Boeing 777-9 aircraft, marking its first deal with Boeing in 12 years, despite concerns over the safety record of Boeing aircraft [7] - The long delivery timeline for the 777-9 model raises potential issues regarding aircraft aging and maintenance [7] Energy Sector Updates - The State Grid reported record electricity usage due to high temperatures, with peak load reaching 1.233 billion kilowatts, an increase of 53 million kilowatts from last year [8] - Coal prices have risen significantly, impacting the steel industry, which is maintaining high production levels [8] Automotive Sector Performance - XPeng Motors reported a record monthly delivery of 36,717 vehicles in July, a year-on-year increase of 229.4% [10] - The company is expanding its presence in Europe, with significant sales growth and new model launches [11][12]

承董事會命 康希諾生物股份公司 Xuefeng YU 董事長 香港，2025年8月6日 （股份代號：6185） 董事會會議通告 康 希 諾 生 物 股 份 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議將於2025年8月20日（星 期 三）舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 公 司 及 其 附 屬公司截至2025年6月30日止六個月的中期業績及其發佈，以及考慮建議派發中 期 股 息（如 有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 於本通告日期，本公司董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博 士 及王靖女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建忠 先生及張耀樑先生。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年8月6日 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 132,670,900 | | 0 | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 132,670,900 | | 0 | | 132,670,900 | | 2. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 (註 ...

8月6日，上证指数涨0.45%，收报3633.99点，恒生指数涨0.03%，收报24910.63点。 康希诺AH溢价达85.6%，位居AH股溢价率第40位。当日收盘，康希诺A股报88.48元，涨幅6.13%，H股 报52.05港元，上涨9.21%。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 本文源自：金融界 作者：行情君 资料显示，康希诺生物股份公司2009年成立于中国,以在世界范围内提供预防和治疗感染类疾病的解决 方案为己任,专注于创新、优质、可及的人用疫苗的研发、生产和商业化,是行业领先的高科技生物制品 企业。康希诺生物的使命始终是"为全球提供创新、优质、可及的疫苗",以达到"创新不止,世界无疫"的 企业愿景。公司已登陆香港联交所主板H股(股票代码6185.HK)和上海证券交易所科创板A股(股票代码 688185),是中国科创板开板以来首支"A+H"疫苗股。 ...

格隆汇8月6日丨康希诺生物(06185.HK)宣布，董事会会议将于2025年8月20日（星期三）举行，藉以 （其中包括）考虑及批准公司及其附属公司截至2025年6月30日止六个月的中期业绩及其发布，以及考 虑建议派发中期股息（如有）。 ...

（股份代號：6185） 董事會會議通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 康 希 諾 生 物 股 份 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議將於2025年8月20日（星 期 三）舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 公 司 及 其 附 屬公司截至2025年6月30日止六個月的中期業績及其發佈，以及考慮建議派發中 期 股 息（如 有）。 承董事會命 康希諾生物股份公司 Xuefeng YU 董事長 香港，2025年8月6日 於本通告日期，本公司董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博 士 及王靖女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建忠 先生及張耀樑先生。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 增加 / 減少 (-) | | | | 0 | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 2. 股份分類 | 普通股 | 股份類別 | ...